Frequency and characterization of p53 mutations in clinically localized prostate cancer

By Hall M.C.   Navone N.M.   Troncoso P.   Pollack A.   Zagars G.K.   von Eschenbach A.C.   Conti C.J.   Chung L.W.K.  

Urology, Vol. 45, Iss. 3, 1995-03 ,pp. : 470-475

Elsevier

Access to resources Recommend Favorite

Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer

By Bjork T.   Piironen T.   Pettersson K.   Lovgren T.   Stenman U.-H.   Oesterling J.E.   Abrahamsson P.-A.   Lilja H.  

Urology, Vol. 48, Iss. 6, 1996-12 ,pp. : 882-888

Elsevier

Access to resources Recommend Favorite

Review of staging modalities in clinically localized prostate cancer

By Perrotti M.   Pantuck A.   Rabbani F.   Israeli R.S.   Weiss R.E.  

Urology, Vol. 54, Iss. 2, 1999-08 ,pp. : 208-214

Elsevier

Access to resources Recommend Favorite

p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy

By Huang A.   Gandour-Edwards R.   Rosenthal S.A.   Siders D.B.   Deitch A.D.   Devere White R.W.  

Urology, Vol. 51, Iss. 2, 1998-02 ,pp. : 346-351

Elsevier

Access to resources Recommend Favorite

Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer

By Dillioglugil O.   Leibman B.D.   Kattan M.W.   Seale-Hawkins C.   Wheeler T.M.   Scardino P.T.  

Urology, Vol. 50, Iss. 1, 1997-07 ,pp. : 93-99

Elsevier

Access to resources Recommend Favorite